Juno Therapeutics Inc (NASDAQ:JUNO) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday. They currently have a $53.00 target price on the biopharmaceutical company’s stock. Vetr‘s price objective indicates a potential upside of 23.31% from the company’s previous close. Other […]
